Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer

被引:0
|
作者
Xing, Zhiwei [1 ]
Gao, Yanan [2 ]
Shi, Yaxuan [2 ]
Gao, Ziyu [1 ]
Liu, Caixia [1 ]
机构
[1] Inner Mongolia Med Univ, Dept Oncol, Affiliated Hosp, 1 Tongdao North Rd, Hohhot 010010, Inner Mongolia, Peoples R China
[2] Inner Mongolia Med Univ, Grad Sch, Hohhot 010010, Inner Mongolia, Peoples R China
关键词
PI3K/Akt/mTOR signaling; 5-Fluorouracil; Gastric cancer; Chemoresistance; BREAST-CANCER; EXPRESSION; CELLS; 5-FU; CHEMOTHERAPY; PROGNOSIS;
D O I
10.1007/s12033-023-00966-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background At present, 5-Fluorouracil (5-FU) is a crucial anti-cancer drug and is widely used for the treatment of various carcinomas, including gastric cancer (GC). The resistance of GC cells to 5-FU is still a matter of great concern. Objective To illustrate the role of PI3K/Akt/mTOR signaling in regulating the cell cycle progression and migration of 5-FU-resistant GC cells. Material and Methods After the establishment of drug-resistant GC cell lines, the effects of 5-FU and/or BEZ235 (the dual inhibitor of PI3K and mTOR) on the activity of parental or drug-resistant GC cells were explored. The viability and localization of GC cells (MKN-45 and MKN-74) and their drug-resistant cells (MKN-45/R and MKN-74/R) were assessed using MTT assays and immunofluorescence staining. The impacts of 5-FU and/or BEZ235 on GC cell cycle progression and cell migration were assessed via flow cytometry analyses and wound healing assays, respectively. GC tissues were collected from patients with GC sensitive or refractory to 5-FU chemotherapy. RT-qPCR and western blot were conducted to measure PI3K, AKT, and mTOR levels in GC cells or tissues. Results After 5-FU treatment, GC cells displayed 5-FU resistance and the viability of drug-resistant cells (MKN-45/R and MKN-74/R) was higher than that of parental cells (MKN-45 and MKN-74). The IC50 values for MKN-45 and MKN-45/R were 8.93 ug/ml and 140 ug/ml, and the values for MKN-74 and MKN-74/R were 3.93 ug/ml and 114.29 ug/ml. Additionally, the PI3K/Akt/mTOR signaling pathway was activated in drug-resistant GC cells and tumor tissues of patients refractory to 5-FU chemotherapy, as evidenced by high PI3K, Akt, and mTOR levels in MKN-45/R, MKN-74/R, and GC tissues resistant to 5-FU. BEZ235 promoted cell cycle arrest and suppressed the migration of GC cells. Moreover, the combination of BEZ235 and 5-FU led to more effective suppressive influence on cell cycle progression and cell migration relative to the single 5-FU or BEZ235 treatment. Conclusions Silencing of the PI3K/Akt/mTOR signaling pathway suppressed the 5-FU resistance of GC cells.
引用
收藏
页码:3640 / 3654
页数:15
相关论文
共 50 条
  • [21] Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway
    Yu, Jie-ru
    Liu, Yu-yue
    Gao, Yang-yang
    Qian, Li-hui
    Qiu, Jia-lin
    Wang, Pei-pei
    Zhang, Guang-ji
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 324
  • [22] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [23] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Antonino Glaviano
    Aaron S. C. Foo
    Hiu Y. Lam
    Kenneth C. H. Yap
    William Jacot
    Robert H. Jones
    Huiyan Eng
    Madhumathy G. Nair
    Pooyan Makvandi
    Birgit Geoerger
    Matthew H. Kulke
    Richard D. Baird
    Jyothi S. Prabhu
    Daniela Carbone
    Camilla Pecoraro
    Daniel B. L. Teh
    Gautam Sethi
    Vincenzo Cavalieri
    Kevin H. Lin
    Nathalie R. Javidi-Sharifi
    Eneda Toska
    Matthew S. Davids
    Jennifer R. Brown
    Patrizia Diana
    Justin Stebbing
    David A. Fruman
    Alan P. Kumar
    Molecular Cancer, 22
  • [24] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [25] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [26] The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
    Matsuoka, Tasuku
    Yashiro, Masakazu
    CANCERS, 2014, 6 (03) : 1441 - 1463
  • [27] Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer
    Akbarzadeh, Maryam
    Mihanfar, Ainaz
    Akbarzadeh, Shabnam
    Yousefi, Bahman
    Majidinia, Maryam
    LIFE SCIENCES, 2021, 285
  • [28] PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
    Glaviano, Antonino
    Foo, Aaron S. C.
    Lam, Hiu Y.
    Yap, Kenneth C. H.
    Jacot, William
    Jones, Robert H.
    Eng, Huiyan
    Nair, Madhumathy G.
    Makvandi, Pooyan
    Geoerger, Birgit
    Kulke, Matthew H.
    Baird, Richard D.
    Prabhu, Jyothi S.
    Carbone, Daniela
    Pecoraro, Camilla
    Teh, Daniel B. L.
    Sethi, Gautam
    Cavalieri, Vincenzo
    Lin, Kevin H.
    Javidi-Sharifi, Nathalie R.
    Toska, Eneda
    Davids, Matthew S.
    Brown, Jennifer R.
    Diana, Patrizia
    Stebbing, Justin
    Fruman, David A.
    Kumar, Alan P.
    MOLECULAR CANCER, 2023, 22 (01)
  • [29] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    HaiXia Li
    JianFang Zeng
    Keng Shen
    Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
  • [30] Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
    Ouissam, Al Jarroudi
    Hind, Chibani
    Aziz, Brahmi Sami
    Said, Afqir
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16